Life Extension Final Clerance Sale

HIV/AIDS References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Singh A et al. Cure for HIV: New possibility on horizon. J Pharm Bioallied Sci. 2011 Jul;3(3):461-4.
  2. Killian, M. S., Levy, J. A. "HIV/AIDS: 30 Years of Progress and Future Challenges." Eur J Immunol 41.12 (2011): 3401-11.
  3. Bhaskaran, K., Hamouda, O., Sannes, M., et al. "Changes in the Risk of Death After HIV Seroconversion Compared with Mortality in the General Population." JAMA 300.1 (2008): 51-9.
  4. Giusti, A., Penco, G., Pioli, G. "Vitamin D Deficiency in HIV-Infected Patients: a Systematic Review."Nutr Diet Supp 3 (2011): 101–111.
  5. Escote X et al. Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. J Acquir Immune Defic Syndr. 2011 May;57(1):16-23.
  6. Tien PC et al. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):369-76.
  7. Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S86-92.
  8. Palios J et al. The Pathophysiology of HIV-/HAART-Related Metabolic Syndrome Leading to Cardiovascular Disorders: The Emerging Role of Adipokines. Exp Diabetes Res. 2012;2012:103063. Epub 2011 Dec 8.
  9. Campbell N. A., Reece, J. B., Urry, L. A., et al. Biology. 8th ed. San Francisco: Benjamin Cummings; 2008.
  10. Coakley E et al. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis. 2005 Feb;18(1):9-15.
  11. Agosto LM, Liszewski MK, Mexas A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology. 2011 Jan;409(1):46-53.
  12. Onyancha, O. B., Ocholla, D. N. "Is HIV/AIDS in Africa Distinct? What Can We Learn From an Analysis of the Literature?" Scientometrics 79.1 (2009): 000–000.
  13. Markovitz, D. M. "Infection with the Human Immunodeficiency Virus Type 2." Ann Intern Med 118.3 (1993): 211-8. http://www.annals.org/content/118/3/211.abstract
  14. de Silva, T. I., Cotten, M., Rowland-Jones, S. L. "HIV-2: the Forgotten AIDS Virus." Trends Microbiol 16.12 (2008): 588-95. http://www.ncbi.nlm.nih.gov/pubmed/18964021
  15. Popper, S. J., Sarr, A. D., Travers, K. U., et al. "Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV-1 and HIV-2." J Infect Dis. 1999;180(4):1116-21.
  16. MacNeil, A., Sankale, J. L., Meloni, S. T., et al. "Long-Term Intrapatient Viral Evolution during HIV-2 Infection." J Infect Dis 195.5 (2007): 726-33.
  17. Foxall, R. B., Albuquerque, A. S., Soares, R. S., et al. "Memory and Naïve-Like Regulatory CD4+ T Cells Expand During HIV-2 Infection in Direct Association with CD4+ T-Cell Depletion Irrespectively of Viremia." AIDS 25.16 (2011): 1961-70. http://www.ncbi.nlm.nih.gov/pubmed/21811143
  18. Pepin, J., Morgan, G., Dunn, D., et al. "HIV-2-Induced Immunosuppression among Asymptomatic West African Prostitutes: Evidence That HIV-2 Is Pathogenic, but Less So Than HIV-1." AIDS 5.10 (1991): 1165-72. http://www.ncbi.nlm.nih.gov/pubmed/1786143
  19. Shi, Y., Brandin, E., Vincic, E., et al. "Evolution of Human Immunodeficiency Virus Type 2 Coreceptor Usage, Autologous Neutralization, Envelope Sequence and Glycosylation." J Gen Virol 86.Pt 12 (2005): 3385-96.
  20. Chan, M. L., Petravic, J., Ortiz, A. M., et al. "Limited CD4+ T Cell Proliferation Leads to Preservation of CD4+ T Cell Counts in SIV-Infected Sooty Mangabeys." Proc Biol Sci 277.1701 (2010): 3773-81.
  21. Hahn, B. H., Shaw, G. M., De Cock, K. M, et al. "AIDS as a Zoonosis: Scientific and Public Health Implications." Science 287.5453 (2000): 607-14. http://www.ncbi.nlm.nih.gov/pubmed/10649986
  22. Gao, F., Bailes, E., Robertson, D. L., et al. "Origin of HIV-1 in the Chimpanzee Pan troglodytes troglodytes." Nature 397.6718 (1999): 436-41. http://www.ncbi.nlm.nih.gov/pubmed/9989410
  23. Pilcher, C. D., Joaki, G., Hoffman, I. F., et al. "Amplified Transmission of HIV-1: Comparison of HIV-1 Concentrations in Semen and Blood during Acute and Chronic Infection." AIDS 21.13 (2007): 1723-30. http://www.ncbi.nlm.nih.gov/pubmed/17690570
  24. Cohen, M. S., Hellmann, N., Levy, J. A., et al. "The Spread, Treatment, and Prevention of HIV-1: Evolution of a Global Pandemic." J Clin Invest 118.4 (2008): 1244-54. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276790/
  25. Kaul, R., Pettengell, C., Sheth, P. M., et al. "The Genital Tract Immune Milieu: an Important Determinant of HIV Susceptibility and Secondary Transmission." J Reprod Immunol 77. 1 (2008): 32-40. http://www.ncbi.nlm.nih.gov/pubmed/17395270
  26. Salazar-Gonzalez, J. F., Salazar M. G., Learn, G. H., et al. "Origin and Evolution of HIV-1 in Breast Milk Determined by Single-Genome Amplification and Sequencing." J Virol 85.6 (2011): 2751-63. http://www.ncbi.nlm.nih.gov/pubmed/21191008
  27. Gantt, S., Carlsson, J., Heath, L., et al. "Genetic Analyses of HIV-1 Env Sequences Demonstrate Limited Compartmentalization in Breast Milk and Suggest Viral Replication within the Breast That Increases with Mastitis." J Virol 84.20 (2010): 10812-9. http://www.ncbi.nlm.nih.gov/pubmed/20660189
  28. Permar, S.R., Kang, H.H., Wilks, A.B., et al. "Local Replication of Simian Immunodeficiency Virus in the Breast Milk Compartment of Chronically Infected, Lactating Rhesus Monkeys." Retrovirology 7 (2010): 7. http://www.retrovirology.com/content/7/1/7
  29. Gray, R. R., Salemi, M., Lowe, A., et al. "Multiple Independent Lineages of HIV-1 Persist in Breast Milk and Plasma." AIDS 25.2 (2011): 143-52. http://www.ncbi.nlm.nih.gov/pubmed/21173592
  30. Dwyre, D. M., Fernando, L. P., Holland, P. V. "Hepatitis B, Hepatitis C and HIV Transfusion-Transmitted Infections in the 21st Century." Vox Sang 100.1 (2011): 92-8. http://www.ncbi.nlm.nih.gov/pubmed/21175659
  31. Raguin, G., Lepretre, A., Ba, I., et al. "Drug Use and HIV in West Africa: a Neglected Epidemic." Trop Med Health 16.9 (2011): 1131-3. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2011.02806.x/full
  32. Boily, M. C., Baggaley, R. F., Wang, L., et al. "Heterosexual Risk of HIV-1 Infection per Sexual Act: Systematic Review and Meta-Analysis of Observational Studies." Lancet Infect Dis 9.2 (2009): 118-29.
  33. Marinda, E. T., Moulton, L. H., Humphrey, J. H., et al. "In Utero and Intra-Partum HIV-1 Transmission and Acute HIV-1 Infection during Pregnancy: Using the BED Capture Enzyme-Immunoassay as a Surrogate Marker for Acute Infection." Int J Epidemiol 40.4 (2011): 945-54. http://ije.oxfordjournals.org/content/early/2011/04/05/ije.dyr055.abstract
  34. Arya, M., Levison, J., Giordano, T. P. "Ongoing Barriers to HIV Testing During Pregnancy: A Need for Media Campaigns Addressing Low Knowledge about Perinatal HIV Transmission among Women in the United States." AIDS Patient Care STDs 24.2 (2010): 71-2.
  35. Liang K, Gui X, Zhang YZ, et al. "A Case Series of 104 Women Infected With HIV-1 via Blood Transfusion Postnatally: High Rate of HIV-1 Transmission to Infants through Breast-Feeding." J Infect Dis 200.5 (2009): 682-6.
  36. Royce, R. A., Seña, A., Cates, W. Jr., et al. "Sexual Transmission of HIV." N Engl J Med 336.15 (1997): 1072-8.
  37. McGowan I. Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect. 84.6 (2008): 413-7.
  38. Baggaley, R. F., White, R. G., Boily, M. C. "HIV Transmission Risk through Anal Intercourse: Systematic Review, Meta-Analysis and Implications for HIV Prevention." Int J Epidemiol 39.4 (2010):1048-63. http://ije.oxfordjournals.org/content/39/4/1048.full
  39. Saini R, Saini S, Sharma S. "Oral Sex, Oral Health and Orogenital Infections." J Glob Infect Dis 2.1 (2010): 57-62. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840968/
  40. Sandlin, M. I., Johnston, C., Bowe, D., et al. "Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex with Men." Sex Transm Dis 38.9 (2011): 833-6.
  41. Corbett, E. L., Steketee, R. W., ter Kuile, F. O., et al. "HIV-1/AIDS and the Control of Other Infectious Diseases in Africa." Lancet 359.9324 (2002): 2177-87.
  42. Boulton, I. C., Gray-Owen, S. D. "Neisserial Binding to CEACAM1 Arrests the Activation and Proliferation of CD4+ T Lymphocytes." Nat Immunol 3.3 (2002): 229-36.
  43. Pask, A. J., McInnes, K. J., Webb, D. R., et al. "Topical Oestrogen Keratinises the Human Foreskin and May Help Prevent HIV Infection." PLoS One 3.6 (2008): e2308. http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0002308
  44. Donoval, B. A., Landay, A. L., Moses, S., et al. "HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections." Am J Clin Pathol 125.3 (2006): 386-91.
  45. Bell, S.K., McMickens, C.L., Selby, K. Biographies of Disease: AIDS. USA: Sigall K. Bell; 2011.
  46. Pantaleo G, et al. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993 Feb 4;328(5):327-35.
  47. Hollingsworth, T. D., Anderson, R. M., Fraser, C. "HIV-1 Transmission, by Stage of Infection." J Infect Dis 198.5 (2008): 687-93.
  48. Wawer, M. J., Gray, R. H., Sewankambo, N. K., et al. "Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda." J Infect Dis 191.9 (2005): 1403-9. http://www.ncbi.nlm.nih.gov/pubmed/15809897
  49. Pilcher, C. D., Tien, H. C., Eron, J. J., Jr, et al. "Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV." J Infect Dis 189.10 (2004): 1785-92. http://jid.oxfordjournals.org/content/189/10/1785.long
  50. Read, J. S.; Committee on Pediatric AIDS, American Academy of Pediatrics. "Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States." Pediatrics 120.6 (2007): e1547-62. http://www.ncbi.nlm.nih.gov/pubmed/18055670
  51. Pilcher, C. D., Christopoulos, K. A., Golden, M. "Public Health Rationale for Rapid Nucleic Acid or P24 Antigen Tests for HIV." J Infect Dis 201 Suppl 1 (2010): S7-15.
  52. Chavez, P., Wesolowski, L., Patel, P., et al. "Evaluation of the Performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay." J Clin Virol 52 Suppl 1 (2011):S51-5. http://www.ncbi.nlm.nih.gov/pubmed/21983253
  53. Bischof, J. J., Kuruc, J. D., Embry, J. A., et al. "Prospective Study of the ARCHITECT HIV Ag/Ab Combo Fourth Generation Assay to Detect HIV Infection in Sexually Transmitted Infection Clinics." AIDS 25.15 (2011): 1927-9. http://www.ncbi.nlm.nih.gov/pubmed/21811138
  54. Pandori MW, Hackett J Jr, Louie B, et al. "Assessment of the Ability of a Fourth-Generation Immunoassay for Human Immunodeficiency Virus (HIV) Antibody and P24 Antigen Detect Both Acute and Recent HIV Infections in a High-Risk Setting." J Clin Microbiol 47.8 (2009): 2639-42. http://jcm.asm.org/content/47/8/2639.full
  55. Fiebig, E. W., Wright, D. J., Rawal, B. D., et al. "Dynamics of HIV Viremia and Antibody Seroconversion in Plasma Donors: Implications for Diagnosis and Staging of Primary HIV Infection." AIDS 17.13 (2003): 1871-9.
  56. Morris, S. R., Little, S. J., Cunningham, T., et al. "Evaluation of an HIV Nucleic Acid Testing Program with Automated Internet and Voicemail Systems to Deliver Results." Ann Intern Med 152.12 (2010): 778-85.
  57. Schneider, E., Whitmore, S., Glynn, K. M., et al. "Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008." MMWR Recomm Rep 57.RR-10 (2008): 1-12.
  58. University of California, San Francisco (UCSF). "Blood Cell Test For HIV Treatment Monitoring Is Cheaper But Just As Effective." Medical News Today. MediLexicon, Intl., 2 Dec. 2011. Web. 13 Jan. 2012. http://www.medicalnewstoday.com/releases/238550.php
  59. Cohen, M. S., Chen, Y. Q., McCauley, M., et al. "Prevention of HIV-1 infection with early antiretroviral therapy." N Engl J Med 365.6 (2011): 493-505. http://www.ncbi.nlm.nih.gov/pubmed/21767103 http://www.nih.gov/news/health/dec2011/niaid-22.htm
  60. Rizzardi, G. P., De Boer, R. J., Hoover, S., et al. "Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA." J Clin Invest105.6 (2000): 777-82. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC377467/
  61. Aberg, J. A., Kaplan, J. E., Libman, H., et al. "Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America." Clin Infect Dis49.5 (2009): 651-81.
  62. Cervia, J. S., Smith, M. A. "Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor." Clin Infect Dis 37.8 (2003): 1102-6.
  63. Jegede, O., Babu, J., Di Santo, R., et al. "HIV Type 1 Integrase Inhibitors: from Basic Research to Clinical Implications." AIDS Rev 10.3 (2008): 172-89.
  64. Yazdanpanah, Y., Fagard, C., Descamps, D., et al. "High Rate of Virologic Suppression with Raltegravir Plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial." Clin Infect Dis 49.9 (2009): 1441-9.
  65. Graham, S. M., Masese, L., Gitau, R., et al. "Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV-1 Shedding Among Women Initiating Treatment." J Infect Dis 202.10 (2010):1538-42.
  66. Lockman, S., Hughes, M. D., McIntyre, J., et al. "Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure." N Engl J Med 363.16 (2010): 1499-509.
  67. Volberding, P. A., Deeks, S. G. "Antiretroviral Therapy and Management of HIV Infection." Lancet 376.9734 (2010): 49-62.
  68. Sharma B. "Anti-HIV-1 Drug Toxicity and Management Strategies." Neurobehav HIV Med (2011): 327-40.
  69. McCord A et al. Milk thistle may help improve liver health in people with HIV and hepatitis C. Proj Inf Perspect. 2008 Sep;(46):18. No abstract available.
  70. Payer BA, Reiberger T, Rutter K, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol. 49.2 (2010):131-3.
  71. Goepp J. The Drug Virtually Everyone Should Ask their Doctor About. Life Extension Magazine, Nov. 2010.
  72. Fitch K et al. Effects of Lifestyle Modification and Metformin on Atherosclerotic Indices among HIV-Infected Patients with the Metabolic Syndrome. AIDS. 2011 Dec 7. [Epub ahead of print]
  73. Diehl La et al. Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care STDS. 2008 Oct;22(10):779-86.
  74. van Wijk JP, Hoepelman AI, de Koning EJ, et al. Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):228-33.
  75. Hadigan C et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000 Jul 26;284(4):472-7.
  76. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem. 2010 Apr 14;58(7):4141-4.
  77. Andrade-Cetto A, Vazquez RC. Gluconeogenesis inhibition and phytochemical composition of two Cecropia species. J Ethnopharmacol. 2010 Jul 6;130(1):93-7.
  78. Rodriguez de Sotillo DV, Hadley M, Sotillo JE. Insulin receptor exon 11+/- is expressed in Zucker (fa/fa) rats, and chlorogenic acid modifies their plasma insulin and liver protein and DNA. J Nutr Biochem. 2006 Jan;17(1):63-71.
  79. Nagendran MV. Effect of green coffee bean extract (GCE), High in Chlorogenic Acids, on Glucose Metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida. October 1-5, 2011.
  80. Diallo M et al. Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1037-45.
  81. Sirskyj D et al. Disruption of the gamma c cytokine network in T cells during HIV infection. Cytokine. 2008 Jul;43(1):1-14. Epub 2008 Apr 15.
  82. Martin BK et al. ty of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):428-33.
  83. Sabbatini F et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLoS One. 2010 Nov 29;5(11):e14119.
  84. Chahroudi A et al. Interleukin-7 in HIV pathogenesis and therapy. Eur Cytokine Netw. 2010 Sep;21(3):202-7. Epub 2010 Aug 20.
  85. Walter J et al. High concentrations of interleukin 15 in breast milk are associated with protection against postnatal HIV transmission. J Infect Dis. 2009 Nov 15;200(10):1498-502.
  86. d’Ettorre G et al. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. AIDS. 2002 Jan 25;16(2):181-8.
  87. Williams LD et al. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol. 2011 Mar;85(5):2316-24. Epub 2010 Dec 15.
  88. Moreno, S., Miralles, C., Negredo, E., et al. "Disorders of body fat distribution in HIV-1-infected patients." AIDS Rev 11.3 (2009): 126-34. http://www.ncbi.nlm.nih.gov/pubmed/19654854
  89. Stanley, T. L., Grinspoon, S. K. "GH/GHRH Axis in HIV Lipodystrophy." Pituitary 12.2 (2009): 143-52.
  90. Sweeney, L. L., Brennan, A. M., Mantzoros, C. S. "The Role of Adipokines in Relation to HIV Lipodystrophy." AIDS 21.8 (2007): 895-904.
  91. Rietschel, P., Hadigan, C., Corcoran, C., et al. "Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy." J Clin Endocrinol Metab 86.2 (2001): 504-10.
  92. Grunfield, C., Thompson, M., Brown, S.J., et al. “Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.” J Acquir Immune Defic Syndr 45.3 (2007):286-97.
  93. Lo, J., You, S. M., Wei, J., et al. "Relationship of Peak Growth Hormone to Cardiovascular Parameters, Waist Circumference, Lipids and Glucose in HIV-Infected Patients and Healthy Adults." Clin Endocrinol (Oxf) 71.6 (2009): 815-22. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889024/
  94. Benedini, S., Terruzzi, I., Lazzarin, A., et al. "Recombinant Human Growth Hormone: Rationale for Use in the Treatment of HIV-Associated Lipodystrophy." BioDrugs 22.2 (2008): 101-12.
  95. Sivakumar, T., Mechanic, O., Fehmie, D. A., et al. "Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials." HIV Med 12.8 (2011): 453-62. http://www.medscape.com/viewarticle/748585
  96. Leung, V. L., Glesby, M. J. "Pathogenesis and Treatment of HIV Lipohypertrophy." Curr Opin Infect Dis 24.1 (2011): 43-9.
  97. Brown, M. "Skeletal Muscle and Bone: Effect of Sex Steroids and Aging." Adv Physiol Educ 32.2 (2008): 120-6. http://www.ncbi.nlm.nih.gov/pubmed/18539850,
  98. Blouin, K., Boivin, A., Tchernof, A. "Androgens and Body Fat Distribution." J Steroid Biochem Mol Biol 108.3-5 (2008): 272-80.
  99. Lang, T. F. "The Bone-Muscle Relationship in Men and Women." J Osteoporos 2011 (2011): 702735.
  100. Rochira, V., Zirilli, L., Orlando, G., et al. "Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-Era." PLoS One 6.12 (2011): e28512. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028512
  101. Dobs A. "Role of Testosterone in Maintaining Lean Body Mass and Bone Density in HIV-Infected Patients." Int J Impot Res 15 Suppl 4 (2003): S21-5.
  102. Rietschel, P., Corcoran, C., Stanley, T., et al. "Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy." Clin Infect Dis 31.5 (2000): 1240-4.
  103. Kopicko, J. J., Momodu, I., Adedokun A., et al. "Characteristics of HIV-Infected Men With Low Serum Testosterone Levels." Int J STD AIDS 10.12 (1999): 817-20.
  104. Andersen, O., Pedersen, S. B., Svenstrup, B., et al. "Circulating Sex Hormones and Gene Expression of Subcutaneous Adipose Tissue Oestrogen and Alpha-Adrenergic Receptors in HIV-Lipodystrophy: Implications for Fat Distribution." Clin Endocrinol (Oxf) 67.2 (2007): 250-8. http://www.ncbi.nlm.nih.gov/pubmed/17524033
  105. Kong, A., Edmonds, P. "Testosterone Therapy in HIV Wasting Syndrome: Systematic Review and Meta-Analysis." Lancet Infect Dis 2.11 (2002): 692-9. http://www.ncbi.nlm.nih.gov/pubmed/12409050
  106. Johns, K., Beddall, M. J., Corrin, R. C. "Anabolic Steroids for the Treatment of Weight Loss in HIV-Infected Individuals." Cochrane Database Syst Rev 4 (2005): CD005483.
  107. Bhasin, S., Parker, R. A., Sattler, F., et al. "Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity." J Clin Endocrin Metabl 92.3 (2007): 1049-57.
  108. Christeff N et al. Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology. 1997;22 Suppl 1:S11-8.
  109. TreatmentUpdate. [no authors listed] Changes in DHEA levels in people taking anti-HIV therapy. TreatmentUpdate. 2001 Winter;12(10):6-7.
  110. Christeff N et al. Longitudinal evolution of HIV-1-associated lipodystrophy is correlated to serum cortisol:DHEA ratio and IFN-alpha. Eur J Clin Invest. 2002 Oct;32(10):775-84.
  111. Abrams DI et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses. 2007 Jan;23(1):77-85.
  112. Poretsky L et al. Metabolic and hormonal effects of oral DHEA in premenopausal women with HIV infection: a randomized, prospective, placebo-controlled pilot study. Horm Metab Res. 2009 Mar;41(3):244-9. Epub 2008 Sep 22.
  113. Rabkin JG et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry. 2006 Jan;163(1):59-66.
  114. Clark RA et al. Clinical manifestations and predictors of survival in older women infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):341-5.
  115. Hütter, G., Nowak, D., Mossner, M., et al. "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation." N Engl J Med. 360.7 (2009): 692-8. http://www.nejm.org/doi/full/10.1056/NEJMoa0802905
  116. Ando, D. Nichol, G. Abst.# H2-794a: "HAART Treatment Interruption following Adoptive Transfer of Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load." Late-Breaker Poster Session: Antiretroviral Therapy of HIV-1 Infection, 11:15 a.m. - 1:15 p.m. CT, Sunday, September 18, 2011. http://bit.ly/zoAOm0 http://www.technologyreview.com/biomedicine/38630/
  117. Fisher, K. "Wasting and Lipodystrophy in Patients Infected with HIV: A Practical Approach in Clinical Practice." AIDS Read 11.3 (2001): 132-3, 137-40, 147. http://www.medscape.com/viewarticle/410373
  118. Somarriba, G., Neri, D., Schaefer, N., Miller, T.L. "The Effect of Aging, Nutrition, and Exercise during HIV Infection." HIV AIDS (Aukl) 2 (2010): 191-201. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218696
  119. Ahoua, L., Umutoni, C., Huerga, H., et al. "Nutrition Outcomes of HIV-Infected Malnourished Adults Treated With Ready-to-Use Therapeutic Foodin Sub-Saharan Africa: a Longitudinal Study." J Int AIDS Soc 14 (2011):2. http://www.jiasociety.org/content/14/1/2
  120. Gleeson, M., McFarlin, B., Flynn, M. "Exercise and Toll-Like Receptors." Exerc Immunol Rev 12 (2006): 34-53.
  121. Gleeson, M. "Immune Function in Sport and Exercise." J Appl Physiol 103.2 (2007): 693-9. http://jap.physiology.org/content/103/2/693.full
  122. Kawai, K., Kupka, R., Mugusi, F., et al. "A Randomized Trial to Determine the Optimal Dosage of Multivitamin Supplements to Reduceadverse Pregnancy Outcomes Among HIV-Infected Women in Tanzania." Am J Clin Nutr 91.2 (2010): 391-7. http://www.ajcn.org/content/91/2/391.full
  123. Fawzi, W. W., Msamanga, G. I., Spiegelman, D., et al. " A randomized trial of multivitamin supplements and HIV disease progression and mortality." N Engl J Med 351.1 (2004): 23-32. http://www.ncbi.nlm.nih.gov/pubmed/15229304?dopt=Abstract
  124. Mehta, S., Giovannucci, E., Mugusi, F. M., et al. "Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality." PLoS One 5.1 (2010b): e8770.
  125. Tang, A. M., Graham, N. M., Kirby, A. J., et al. "Dietary Micronutrient Intake and Risk of Progression to Acquired Immunodeficiency Syndrome (AIDS) In Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Homosexual Men." Am J Epidemiol 138.11 (1993): 937-51. http://www.ncbi.nlm.nih.gov/pubmed/7903021
  126. Abrams, B., Duncan, D., Hertz-Picciotto, I. "A Prospective Study of Dietary Intake and Acquired Immune Deficiency Syndrome in HIV-Seropositive Homosexual Men." J Acquir Immune Defic Syndr 6.8 (1993): 949-58. http://www.ncbi.nlm.nih.gov/pubmed/8100273?dopt=Abstract
  127. Fawzi, W. W., Msamanga, G. I., Spiegelman, D, et al. "Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania." Lancet 351.9114 (1998): 1477-82.
  128. Mda, S., van Raaij, J. M., Macintyre, U. E., de Villiers, F. P., Kok, F. J. "Improved Appetite after Multi-Micronutrient Supplementation for Six Months in HIV-Infected South African Children." Appetite 54.1 (2010a): 150-5. http://www.sciencedirect.com/science/article/pii/S0195666309006370
  129. Semba, R. D., Ndugwa, C., Perry, R. T., et al. "Effect of Periodic Vitamin A Supplementation of Mortality and Morbidity of Human Immunodeficiency Virus-Infected Children in Uganda: A Controlled Clinical Trial." Nutrition 21.1 (2005): 25-31. http://www.ncbi.nlm.nih.gov/pubmed/15661475
  130. Fawzi, W. W., Mbise, R. L., Hertzmark, E., et al. "A Randomized Trial of Vitamin a Supplements in Relation to Mortality Among Human Immunodeficiency Virus-Infected and Uninfected Children in Tanzania." Pediatr Infect Dis J 18.2 (1999): 127-33. http://journals.lww.com/pidj/Abstract/1999/02000/A_randomized_trial_of_vitamin_A_supplements_in.9.aspx
  131. Coutsoudis, A., Bobat, R. A., Coovadia, H. M., et al. "The Effects of Vitamin A Supplementation on the Morbidity of Children Born to HIV-Infected Women." Am J Public Health 85.8 Pt 1 (1995): 1076-81. http://www.ncbi.nlm.nih.gov/pubmed/7625499
  132. Villamor, R., Mugusi, F., Urassa, W., et al. "A Trial of the Effect of Micronutrient Supplementation on Treatment Outcome, T Cell Counts, Morbidity, and Mortality in Adults with Pulmonary Tuberculosis." J Infect Dis 197.11 (2008): 1499-505. http://www.ncbi.nlm.nih.gov/pubmed/18471061 VIT SUPPS and TB
  133. Mda, S., van Raaij, J. M., de Villiers, F. P., et al. "Short-Term Micronutrient Supplementation Reduces the Duration of Pneumonia and Diarrheal Episodes in HIV-Infected Children." J Nutr 140.5 (2010b): 969-74.
  134. Valko, M., Leibfritz, D., Moncol, J., et al. "Free Radicals and Antioxidants in Normal Physiological Functions and Human Disease." Int J Biochem Cell Biol 39.1 (2007): 44-84. http://www.pinnaclife.com/assets/files/pdf/References/Diabetes/Human-disease.pdf
  135. Oguntibeju, O. O., Esterhuyse A. J., Trute E. J. "Possible Role of Red Palm Oil Supplementation in Reducing Oxidative Stress in HIV/AIDS and TB Patients: a Review." J Medicinal Plants Res 4.3 (2010): 188-196. http://www.academicjournals.org/JMPR/PDF/pdf2010/4Feb/Oguntibeju%20et%20al.pdf
  136. Srinivas, A., Dias, B. F. "Antioxidants in HIV Positive Children." Indian J Pediatr 75.4 (2008): 347-50.
  137. Wanchu, A., Rana, S. V., Pallikkuth, S., Sachdeva, R. K. "Short Communication: Oxidative Stress in HIV-Infected Individuals: a Cross-Sectional Study." AIDS Res Hum Retroviruses 25.12 (2009): 1307-11.
  138. Aquaro, S. Scopelliti, F., Pollicita, M., Perno, C. F. "Oxidative Stress and HIV Infection: Target Pathways for Novel Therapies?" Future HIV Therapy 2.4 (2008): 327-338.
  139. Kashou, A. H., Agarwal, A. "Oxidants and Antioxidants in the Pathogenesis of HIV/AIDS." The Open Reprod Sci J 3 (2011): 154-161. http://benthamscience.com/open/torsj/articles/V003/SI0001TORSJ/154TORSJ.pdf
  140. Bautista, A. P. "Free Radicals, Chemokines, and Cell Injury in HIV-1 and SIV Infections and Alcoholic Hepatitis." Free Radic Biol Med 31.12 (2001): 1527-32. http://www.ncbi.nlm.nih.gov/pubmed/11744325
  141. Deresz, L. F., Sprinz, E., Kramer, A. S., et al. "Regulation of Oxidative Stress in Response to Acute Aerobic and Resistance Exercise in HIV-Infected Subjects: a Case-Control Study." AIDS Care 22.11 (2010): 1410-7.
  142. Ogunro, P. S., Ogungbamigbe, T. O., Ajala, M. O., et al. "Total Antioxidant Status and Lipid Peroxidation in HIV-1 Infected Patients in a Rural Area of South Western Nigeria." Afr J Med Sci 34.3 (2005): 221-5. http://www.ncbi.nlm.nih.gov/pubmed/16749352
  143. Pasupathi P, Ramchandran T, Sindhu PJ, et al. “Enhanced Oxidative Stress Markers and Antioxidant Imbalance in HIV Infection and AIDS Patients. 2009;1(2): 370-80. http://www.banglajol.info/bd/index.php/JSR/article/viewArticle/2295
  144. Bilbis, L. S., Idowu, D. B., Saidu, Y., et al. "Serum Levels of Antioxidant Vitamins and Mineral Elements of Human Immunodeficiency Viruspositive Subjects in Sokoto, Nigeria." Ann Afr Med 9.4 (2010): 235-9.
  145. Wang, X., Chai, H., Yao, Q., et al. "Molecular Mechanisms of HIV Protease Inhibitor-Induced Endothelial Dysfunction." J Acquir Immune Defic Syndr 44.5 (2007): 493-9. http://www.ncbi.nlm.nih.gov/pubmed/17245228
  146. Masiá, M., Padilla, S., Bernal, E., et al. "Influence of Antiretroviral Therapy on Oxidative Stress and Cardiovascular Risk: A Prospective Cross-Sectional Study in HIV-Infected Patients." Clin Ther 29.7 (2007): 1448-55. http://www.ncbi.nlm.nih.gov/pubmed/17825696
  147. Ngondi, J. L., Oben, J., Forkah, D. M., et al. "The Effect of Different Combination Therapies on Oxidative Stress Markers in HIV Infected Patients in Cameroon." AIDS Res Ther 3 (2006): 19.
  148. Tang, A. M., Lanzillotti, J., Hendricks, K, et al. "Micronutrients: Current Issues for HIV Care Providers." AIDS 19.9 (2005): 847-61. TANG 2005
  149. Drain, P. K., Kupka, R., Mugusi, F., et al. "Micronutrients in HIV-Positive Persons Receiving Highly Active Antiretroviral Therapy." Am J Clin Nutr 85.2 (2007): 333-45.
  150. Allard, J. P., Aghdassi, E., Chau, J., et al. "Effects of Vitamin E and C Supplementation on Oxidative Stress and Viral Load in HIV-Infected Subjects." AIDS 12.13 (1998): 1653-9. http://www.ncbi.nlm.nih.gov/pubmed/9764785
  151. Tang, A. M., Graham, N. M., Semba, R. D., et al. "Association between Serum Vitamin A and E Levels and HIV-1 Disease Progression." AIDS 11.5 (1997): 613-20.
  152. Austin, J., Singhal, N., Voigt, R., et al. "A Community Randomized Controlled Clinical Trial of Mixed Carotenoids and Micronutrient Supplementation of Patients with Acquired Immunodeficiency Syndrome." Eur J Clin Nutr 60.11 (2006): 1266-76.
  153. Kaiser, J. D., Campa, A. M., Ondercin, J. P., et al. "Micronutrient Supplementation Increases CD4 Count in HIV-Infected Individuals on Highly Active Antiretroviral Therapy: A Prospective, Double-Blinded, Placebo-Controlled Trial." J Acquir Immune Defic Syndr 42.5 (2006): 523-8. http://www.ncbi.nlm.nih.gov/pubmed/16868496
  154. Markovic, I., Clouse, K. A. "Recent Advances in Understanding the Molecular of HIV-1 Entry and Fusion: Revisiting Current Targets and Considering New Options for Therapeutic Intervention." Curr HIV Res 2.3 (2004): 223-34.
  155. Morris, D., Guerra, C., Donohue, C., et al. "Unveiling the Mechanisms for Decreased Glutathione in Individuals with HIV Infection." Clin Dev Immunol 2012 (2012). http://www.hindawi.com/journals/cdi/2012/734125/
  156. Herzenberg, L. A., De Rosa, S. C., Dubs, J. G., et al. "Glutathione Deficiency Is Associated with Impaired Survival in HIV Disease." Proc Natl Acad Sci U S A 94.5 (1997): 1967-72. http://www.pnas.org/content/94/5/1967.full.pdf
  157. McComsey, G., Southwell, H., Gripshover B, et al. "Effect Of Antioxidants On Glucose Metabolism And Plasma Lipids In HIV-Infected Subjects With Lipoatrophy." J Acquir Immune Defic Syndr33.5 (2003): 605-7.
  158. Standish, L. J., Greene, K. B., Bain, S., et al. "Alternative Medicine Use in HIV-Positive Men and Women: Demographics, Utilization Patterns and Health Status." AIDS Care13.2 (2001): 197-208.
  159. Tantcheva, L. P., Stoeva, E. S., Galabov, A. S., et al. "Effect of Vitamin E and Vitamin C Combination on Experimental Influenza Virus Infection." Methods Find Exp Clin Pharmacol25.4 (2003): 259-64.
  160. Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 7.4 (2007): 355-9.
  161. De Rosa, S. C., Zaretsky, M. D., Dubs, J. G., et al. "N-Acetylcysteine Replenishes Glutathione in HIV Infection." Eur J Clin Invest 30.10 (2000): 915-29. http://www.ncbi.nlm.nih.gov/pubmed/11029607
  162. Visalli, V., Muscoli, C., Sacco, I., et al. "N-Acetylcysteine Prevents HIV Gp 120-Related Damage of Human Cultured Astrocytes: Correlation with Glutamine Synthase Dysfunction." BMC Neurosci 8 (2007): 106.
  163. Li, S., Hattori, T., Kodama, E. N. "Epigallocatechin Gallate Inhibits the HIV Reverse Transcription Step." Antivir Chem Chemother 21.6 (2011): 239-43. http://www.ncbi.nlm.nih.gov/pubmed/21730371
  164. Kawai, K., Tsuno, N. H., Kitayama, J., et al. "Epigallocatechin Gallate, the Main Component of Tea Polyphenol, Binds to CD4 and Interferes with Gp120 Binding." J Allergy Clin Immunol 112.5 (2003): 951-7. http://www.ncbi.nlm.nih.gov/pubmed/14610487
  165. Nance, C. L., Siwak, E. B., Shearer, W. T. "Preclinical Development of the Green Tea Catechin, Epigallocatechin Gallate, as an HIV-1 Therapy." J Allergy Clin Immunol 123. 2 (2009): 459-65.
  166. Williamson, M. P., McCormick, T. G., Nance, C. L., et al. "Epigallocatechin Gallate, the Main Polyphenol in Green Tea, Binds to the T-Cell Receptor, CD4: Potential for HIV-1 Therapy." J Allergy Clin Immunol 118.6 (2006): 1369-74. http://www.ncbi.nlm.nih.gov/pubmed/17157668
  167. Hauber, I., Hohenberg, H., Holstermann, B., et al. "The Main Green Tea Polyphenol Epigallocatechin-3-Gallate Counteracts Semen-Mediated Enhancement of HIV Infection." Proc Natl Acad Sci U S A 106.22 (2009): 9033-8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683882/?tool=pubmed
  168. Jariwalla, R. J., Gangapurkar, B., Pandit, A., et al. "Micronutrient cooperation in the suppression of HIV production in chronically and latently infected cells." Mol Med Report 3.3 (2010): 377-85.
  169. Shay, K. P., Moreau, R. F., Smith, E. J. , et al. " Alpha-Lipoic Acid as a Dietary Supplement: Molecular Mechanisms and Therapeutic Potential." Biochim Biophys Acta 1790.10 (2009): 1149-60. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756298/
  170. Zhang, W.J., Wei, H., Hagen, T., et al. "Alpha-Lipoic Acid Attenuates LPS-Induced Inflammatory Responses By Activating the Phosphoinositide 3-Kinase/Akt Signaling Pathway." Proc Natl Acad Sci USA 104.10 (2007): 4077-82. ZHANG 2007
  171. Jariwalla, R. J., Lalezari, J., Cenko, D., et al. "Restoration of Blood Total Glutathione Status and Lymphocyte Function Following Alpha-Lipoic Acid Supplementation in Patients with HIV Infection." J Altern Complement Med 14.2 (2008): 139-46. http://www.ncbi.nlm.nih.gov/pubmed/18315507
  172. Baur, A., Harrer, T., Peukert, M., et al. "Alpha-Lipoic Acid Is an Effective Inhibitor of Human Immuno-Deficiency Virus (HIV-1) Replication." Klin Wochenschr 69.15 (1991): 722-4. http://www.ncbi.nlm.nih.gov/pubmed/1724477
  173. Suzuki, Y. J., Aggarwal, B. B., Packer, L. " Alpha-Lipoic Acid Is a Potent Inhibitor of NF-Kappa B Activation in Human T Cells." Biochem Biophys Res Commun 189.3 (1992): 1709-15. http://www.ncbi.nlm.nih.gov/pubmed/1482376
  174. Merin, J. P., Matsuyama, M., Kira, T., et al. "Alpha-Lipoic Acid Blocks HIV-1 LTR-Dependent Expression of Hygromycin Resistance in THP-1 Stable Transformants." FEBS Lett 394.1 (1996): 9-13. http://www.ncbi.nlm.nih.gov/pubmed/8925935
  175. Youle, M. "Acetyl-L-Carnitine in HIV-Associated Antiretroviral Toxic Neuropathy." CNS Drugs 21 Suppl 1 (2007a): 25-30; discussion 45-6. http://www.ncbi.nlm.nih.gov/pubmed/17696590
  176. Hart, A. M., Wilson, A. D., Montovani, C., et al. "Acetyl-L-Carnitine: a Pathogenesis Based Treatment for HIV-Associated Antiretroviral Toxic Neuropathy." AIDS 18.11 (2004): 1549-60. http://www.ncbi.nlm.nih.gov/pubmed/15238773
  177. Osio, M., Muscia, F., Zampini, L., et al. "Acetyl-L-Carnitine in the Treatment of Painful Antiretroviral Toxic Neuropathy in Human Immunodeficiency Virus Patients: An Open Label Study." J Peripher Nerv Syst 11.1 (2006): 72-6. http://www.ncbi.nlm.nih.gov/pubmed/16519785
  178. Youle, M., Osio, M, ALCAR Study Group. "A Double-Blind, Parallel-Group, Placebo-Controlled, Multicentre Study of Acetyl L-Carnitine in the Symptomatic Treatment of Antiretroviral Toxic Neuropathy in Patients with HIV-1 Infection." HIV Med 8.4 (2007b): 241-50.
  179. Herzmann, C., Johnson, M. A., Youle, M. "Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy." HIV Clin Trials 6.6 (2005): 344-50. http://www.ncbi.nlm.nih.gov/pubmed/16566084
  180. Valcour, V., Yeh, T. M., Bartt, R., et al. "Acetyl-L-Carnitine and Nucleoside Reverse Transcriptase Inhibitor-Associated Neuropathy in HIV Infection." HIV Med 10.2 (2009): 103-10.
  181. Phillips, T. J., Cherry, C. L., Cox, S., et al. "Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials." PLoS One 5.12 (2010): e14433. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014433
  182. Bikle D. D. "Vitamin D and Immune Function: Understanding Common Pathways." Curr Osteoporos Rep 7.2 (2009): 58-63.
  183. Holick M. F. "High Prevalence of Vitamin D Inadequacy and Implications for Health." Mayo Clin Proc 81.3 (2006): 353-73. http://171.67.112.83/content/81/3/353.full
  184. Rodríguez, M., Daniels, B., Gunawardene, S., et al. "High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients." AIDS Res Hum Retroviruses. 25.1 (2009): 9-14.
  185. Conrado, T., Miranda-Filho, Dde B., Ximenes, R. A., et al. "Vitamin D Deficiency in HIV-Infected Women on Antiretroviral Therapy Living in the Tropics."J Int Assoc Physicians AIDS Care (Chic)10.4 (2011): 239-45. http://jia.sagepub.com/content/10/4/239.short
  186. Adeyemi, O. M., Agniel, D., French, A.L., et al. "Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States." J Acquir Immune Defic Syndr 57.3 (2011): 197-204.
  187. Dao, C. N., Patel, P., Overton, E. T., et al. "Low Vitamin D Among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in A Cohort of HIV-Infected Adults And Comparison to Prevalence Among Adults in the US General Population." Clin Infect Dis. 2011 Feb 1;52(3):396-405. http://cid.oxfordjournals.org/content/52/3/396.short
  188. Kim, J. H., Gandhi, V., Psevdos, G., et al. "Evaluation of Vitamin D Levels Among HIV-Infected Patients in New York City. AIDS Res Hum Retroviruses." (2011). [Epub ahead of print]
  189. Fox, J., Peters, B., Prakash, M., et al. "Improvement in Vitamin D Deficiency Following Antiretroviral Regime Change: Results from the MONET Trial." AIDS Res Hum Retroviruses 27.1 (2011): 29-34. http://www.liebertonline.com/doi/abs/10.1089/aid.2010.0081
  190. Gutiérrez, F., Masiá, M. "The Role of HIV and Antiretroviral Therapy in Bone Disease." AIDS Rev 13.2 (2011): 109-18. http://www.aidsreviews.com/files/2011_13_2_109-118.pdf
  191. Guillemi, S., Harris, M., Bondy, G. P., et al. "Prevalence of Bone Mineral Density Abnormalities and Related Risk Factors in an Ambulatory HIV Clinic Population." J Clin Densitom 13.4 (2010): 456-61.
  192. Post F. A. McCloskey, E. V., Compston J. E. "Prevention of Bone Loss and Management of Fracture Risk in HIV-Infected Individuals: Case Studies and Recommendations for Different Patient Subgroups." Future Virol 6.6 (2011): 769-782.
  193. McComsey, G. A., Tebas, P., Shane, E., et al."Bone Disease in HIV Infection: a Practical Review and Recommendations for HIV Care Providers." Clin Infect Dis. 51.8 (2010): 937-46.
  194. Lake, J. E., Adams, J. S. "Vitamin D in HIV-Infected Patients." Curr HIV/AIDS Rep 8 (2011): 133-141.
  195. Conesa-Botella, A., Florence, E., Lynen, L., et al. "Decrease of Vitamin D Concentration in Patients with HIV Infection on A Non Nucleoside Reverse Transcriptase Inhibitor-Containing Regimen." AIDS Res Ther 7 (2010): 40.
  196. Mueller, N. J., Fux, C. A., Ledergerber, B., et al. "High Prevalence of Severe Vitamin D Deficiency in Combined Antiretroviral Therapy-Naive and Successfully Treated Swiss HIV Patients." AIDS 24.8 (2010): 1127–1134.
  197. Van Den Bout-Van Den Beukel, C. J., Fievez, L., Michels, M., et al. "Vitamin D Deficiency among HIV Type 1-Infected Individuals in the Netherlands: Effects of Antiretroviral Therapy." AIDS Res Hum Retroviruses. 2008;24(11):1375–1382.
  198. Stellbrink, H. J., Orkin, C., Arribas, J. R., et al. "Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study." Clin Infect Dis 51.8 (2010): 963-72.
  199. Carr, A., Hoy, J. "Low Bone Mineral Density with Tenofovir: Does Statistically Significant Mean Clinically Significant?" Clin Infect Dis 51.8 (2010): 973-5.
  200. Grund, B., Peng, G., Gibert. C. L., et al. "Continuous Antiretroviral Therapy Decreases Bone Mineral Density." AIDS 23 (2009): 1519-1529
  201. Gallant, J. E., Staszewski, S., Pozniak, A. L., et al. "Efficacy and Safety of Tenofovir DF Vs Stavudine in Combination Therapy in Antiretroviral Naive Patients: a 3-Year Randomized Trial." JAMA 292 (2004): 191-201.
  202. Childs, K. E., Fishman, S. L., Constable, C., et al. "Short Communication: Inadequate Vitamin D Exacerbates Parathyroid Hormone Elevations in Tenofovir Users." AIDS Res Hum Retroviruses 26.8 (2010): 855-9. http://www.liebertonline.com/doi/abs/10.1089/aid.2009.0308
  203. Welz, T., Childs, K., Ibrahim, F., et al. "Efavirenz is Associated with Severe Vitamin D Deficiency and Increased Alkaline Phosphatase." AIDS 24.12 (2010): 1923-8. http://journals.lww.com/aidsonline/Fulltext/2010/07310/Efavirenz_is_associated_with_severe_vitamin_D.14.aspx?WT.mc_id=HPxADx20100319xMP
  204. Villamor E. "A Potential Role for Vitamin D on HIV Infection?" Nutr Rev 64.5 Pt 1 (2006): 226-33.
  205. Stein, E. M., Yin, M. T., McMahon, D. J., et al. "Vitamin D Deficiency in HIV-Infected Postmenopausal Hispanic and African-American Women." Osteoperos Int 22.2 (2011): 477-87.
  206. Ross, A. C., Judd, S., Kumari, M., et al. "Vitamin D Is Linked to Carotid Intima-Media Thickness and Immune Reconstitution in HIV-Positive Individuals." Antivir Ther 16.4 (2011): 555-63.
  207. Arpadi, S. M., McMahon, D., Abrams, E. J., et al. "Effect of Bimonthly Supplementation with Oral Cholecalciferol on Serum 25-Hydroxyvitamin D Concentrations in HIV-Infected Children and Adolescents." Pediatrics 123.1 (2009): e121-6. http://www.ncbi.nlm.nih.gov/pubmed/19117833
  208. Fryburg, D. A., Mark, R. J., Griffith, B. P., et al. "The Effect of Supplemental Beta-Carotene on Immunologic Indices in Patients with AIDS: a Pilot Study." Yale J Biol Med 68.1-2 (1995): 19-23. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590840/pdf/yjbm00037-0022.pdf
  209. Hanekom, W. A., Yogev, R., Heald, L. M., et al. "Effect of Vitamin A Therapy on Serologic Responses and Viral Load Changes after Influenza Vaccination in Children Infected with the Human Immunodeficiency Virus." J Pediatr 136.4 (2000): 550-2. http://www.ncbi.nlm.nih.gov/pubmed/10753259
  210. Kennedy-Oji, C., Coutsoudis, A., Kuhn, L., et al. "Effects of Vitamin A Supplementation during Pregnancy and Early Lactation on Body Weight of South African HIV-Infected Women." J Health Popul Nutr 19.3 (2001): 167-76.
  211. Semba, R. D., Miotti, P. G., Chiphangwi, J. D., et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 343.8913 (1994): 1593-7. http://www.ncbi.nlm.nih.gov/pubmed/7911919
  212. Villamor, E., Koulinska, I. N., Aboud, S., et al. "Effect of Vitamin Supplements on HIV Shedding in Breast Milk." An J Clin Nutr 92.4 (2010): 881-6. http://www.ajcn.org/content/92/4/881.full
  213. Wiysonge, C. S., Shey, M., Kongnyuy, E. J., et al. "Vitamin A Supplementation for Reducing the Risk of Mother-to-Child Transmission of HIV Infection." Cochrane Database Syst Rev 1 (2011): CD003648.
  214. Kaplan, B. J., Crawford, S. G., Field, C. J., et al. "Vitamins, Minerals, and Mood." Psychol Bull 133.5 (2007): 747-60. http://www.healthwatcher.net/Quackerywatch/Synergy/Kaplan/Research/Vitamins,%20Minerals%20and%20Mood.pdf
  215. Rall, L. C., Meydani, S. N. "Vitamin B6 and Immune Competence. Nutr Rev 51.8 (1993): 217-25. http://www.ncbi.nlm.nih.gov/pubmed/8302491
  216. Tang, A. M., Graham, N. M., Saah, A. J. "Effects of Micronutrient Intake on Survival in Human Immunodeficiency Virus Type 1 Infection." Am J Epidemiol 143.12 (1996): 1244-56. http://aje.oxfordjournals.org/content/143/12/1244.full.pdf
  217. Baum, M. K., Shor-Posner, G., Lu, Y, et al. "Micronutrients and HIV-1 Disease Progression." AIDS 9.9 (1995): 1051-6. http://www.ncbi.nlm.nih.gov/pubmed/8527077
  218. Wall, R., Ross, R. P., Fitzgerald, G. F., et al. "Fatty Acids from Fish: the Anti-Inflammatory Potential of Long-Chain Omega-3 Fatty Acids." Nutr Rev 68.5 (2010): 280-9.
  219. Grinspoon, S., Carr, A. "Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults." N Engl J Med 352.1 (2005): 48-62.
  220. DAD Study Group, Friis-Møller, N., Reiss, P., et al. "Class of antiretroviral drugs and the risk of myocardial infarction." N Engl J Med 356.17 (2007): 1723-35. http://www.nejm.org/doi/full/10.1056/NEJMoa062744
  221. Hellerstein, M. K., Grunfeld, C., Wu, K., et al. "Increased De Novo Hepatic Lipogenesis in Human Immunodeficiency Virus Infection." J Clin End Metab 76 (1993): 559-65.
  222. d'Arminio, A., Sabin, C. A., Phillips, A. N. "Cardio- and Cerebrovascular Events in HIV-Infected Persons." AIDS 18.13 (2004): 1811-7.
  223. Woods, M. N., Wanke, C. A., Ling, P. R., et al. "Effect of a Dietary Intervention and N-3 Fatty Acid Supplementation on Measures of Serum Lipid and Insulin Sensitivity in Persons with HIV." Am J Clin Nutr 90.6 (2009): 1566-78. http://www.ncbi.nlm.nih.gov/pubmed/19846544
  224. Oliveira, J. M., Rondó, P. H. "Omega-3 Fatty Acids and Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Systematic Review and Meta-Analysis." HIV Clin Trials 12.5 (2011): 268-74.
  225. Peters, B. S., Wierzbicki, A. S., Moyle, G., et al. "The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial." Clin Ther (2011) [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/22212377
  226. Wohl, D. A., Tien, H. C., Busby, M., et al. "Randomized Study of the Safety and Efficacy of Fish Oil (Omega-3 Fatty Acid) Supplementation with Dietary and Exercise Counseling for the Treatment of Antiretroviral Therapy-Associated Hypertriglyceridemia." Clin Infect Dis 41.10 (2005): 1498-504.
  227. Carter, V. M., Woolley, I., Jolley, D., et al. "A Randomised Controlled Trial of Omega-3 Fatty Acid Supplementation for the Treatment of Hypertriglyceridemia in HIV-Infected Males on Highly Active Antiretroviral Therapy." Sex Health 4 (2006): 287-90. http://www.ncbi.nlm.nih.gov/pubmed/17112442
  228. Gerber JG, Kitch DW, Fictenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008 Apr;47(4):459-66.
  229. De Truchis, P., Kirstetter, M., Perier, A., et al. "Reduction in Triglyceride Level with N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy: a Randomized Prospective Study." J Acquir Immune Defic Syndr 44.3 (2007): 278-85.
  230. Marshall, K. "Therapeutic Applications of Whey Protein." Altern Med Rev9.2 (2004): 136-56. http://www.megawecare.co.th/file/research/Therapeutic%20Applications%20of%20Whey%20Protein_36.pdf
  231. Sattler, F. R., Rajicic, N., Mulligan, K., et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am J Clin Nutr 88.5 (2008): 1313-21. http://www.ncbi.nlm.nih.gov/pubmed/18996868
  232. Micke, P., Beeh, K. M., Buhl. R. "Effects of Long-Term Supplementation with Whey Proteins on Plasma Glutathione Levels of HIV-Infected Patients." Eur J Nutr41.1 (2002): 12-8.
  233. Hummelen, R., Hemsworth, J., Reid, G. "Micronutrients, N-Acetyl Cysteine, Probiotics and Prebiotics, a Review of Effectiveness in Reducing HIV Progression." Nutrients2.6 (2010): 626-651.
  234. van der Strate BW, Beljaars L, et al. Antiviral activities of lactoferrin. Antiviral Res. 2001 Dec;52(3):225-39.
  235. Swart PJ, Kuipers ME, et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro . AIDS Res Hum Retroviruses. 1996 Jun 10;12(9):769-75.
  236. Swart PJ, Kuipers EM, et al. Lactoferrin: antiviral activity of lactoferrin. Adv Exp Med Biol. 1998;443:205-13.
  237. Berkhout B et al. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. 2002 Aug;55(2):341-55.
  238. Carthagena L et al. Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide. Open Virol J. 2011;5:27-34. Epub 2011 Apr 15.
  239. Defer MC, Dugas B, et al. Impairment of circulating lactoferrin in HIV-1 infection. Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):417-21.
  240. Zuccotti GV et al. Oral lactoferrin in HIV-1 vertically infected children: an observational follow-up of plasma viral load and immune parameters. J Int Med Res. 2006 Jan-Feb;34(1):88-94.
  241. Folkers, K., Langsjoen, P., Nara, Y., et al. "Biochemical Deficiencies of Coenzyme Q10 in HIV-Infection and Exploratory Treatment." Biochem Biophys Res Commun 153.2 (1988): 888-96. http://www.ncbi.nlm.nih.gov/pubmed/3382410
  242. Folkers, K., Hanioka, T., Xia, L. J., et al. "Coenzyme Q10 Increases T4/T8 Ratios of Lymphocytes in Ordinary Subjects and Relevance to Patients Having the AIDS Related Complex." Biochem Biophys Res Commun176.2 (1991): 786-91.
  243. Yamashita S, Yamamoto Y. "Simultaneous Detection of Ubiquinol and Ubiquinone in Human Plasma as a Marker of Oxidative Stress." Anal Biochem250.1 (1997): 66-73.
  244. Batterham, M., Gold, J., Naidoo, D., et al. "A Preliminary Open Label Dose Comparison Using an Antioxidant Regimen to Determine the Effect Onviral Load and Oxidative Stress in Men with HIV/AIDS." Eur J Clin Nutr 55.2 (2001): 107-14. http://www.ncbi.nlm.nih.gov/pubmed/11305623
  245. Rosenfeldt, F. L., Mijch, A., McCrystal, G., et al. "Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy." Int J STD AIDS 16.12 (2005): 827-9. http://www.ncbi.nlm.nih.gov/pubmed/16336769
  246. Cherry, C. L., Mobarok, M., Wesselingh, S. L., et al. "Ubisol-Aqua: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model." Curr HIV Res. 2010 Apr 1;8(3):232-9.
  247. Look, M. P., Rockstroh, J. K., Rao, G. S., et al. "Serum Selenium, Plasma Glutathione (GSH) and Erythrocyte Glutathione Peroxidase (GSH-Px)-Levels in Asymptomatic Versus Symptomatic Human Immunodeficiency Virus-1 (HIV-1)-Infection." Eur J Clin Nutr 51.4 (1997): 266-72. http://www.ncbi.nlm.nih.gov/pubmed/9104578
  248. Hoffmann, P. R., Berry, M. J. "The Influence of Selenium on Immune Responses." Mol Nutr Food Res 52.11 (2008): 1273-80.
  249. Tinggi, U. "Selenium: its role as antioxidant in human health." Environ Health Prev Med 13.2 (2008): 102-8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698273/
  250. Baum, M. K., Miguez-Burbano, M. J., et al. "Selenium and Interleukins in Persons Infected with Human Immunodeficiency Virus Type 1." J Infect Dis 182 Suppl 1 (2000): S69-73. http://jid.oxfordjournals.org/content/182/Supplement_1/S69.long
  251. Campa, A., Shor-Posner, G., Indacochea. F., et al. "Mortality Risk in Selenium-Deficient HIV-Positive Children." J Acquir Immune Defic Syndr Hum Retrovirol 20.5 (1999): 508-13. http://www.ncbi.nlm.nih.gov/pubmed/10225235
  252. Shor-Posner, G., Miguez, M. J., Pineda, L. M., et al. "Impact of Selenium Status on the Pathogenesis of Mycobacterial Disease in HIV-1-Infected Drugusers the Era of Highly Active Antiretroviral Therapy." J Acquir Immune Defic Syndr 29.2 (2002): 169-73.
  253. Hori, K., Hatfield, D., Maldarelli, F., et al. "Selenium Supplementation Suppresses Tumor Necrosis Factor Alpha-Induced Human Immunodeficiency Virus Type 1 Replication in Vitro." AIDS Res Hum Retroviruses 13.15 (1997): 1325-32.
  254. Kalantari, P., Narayan, V., Natarajan, S. K., et al. "Thioredoxin Reductase-1 Negatively Regulates HIV-1 Transactivating Protein Tat-Dependent Transcription in Human Macrophages." J Biol Chem 283.48 (2008): 33183-90. NEED LINK
  255. Kupka, R., Mugusi, F., Aboud, S., et al. "Effect of Selenium Supplements on Hemoglobin Concentration and Morbidity among HIV-1-Infectedtanzanian Women." Clin Infect Dis 48.10 (2009): 1475-8.
  256. Burbano X, Miguez-Burbano MJ, McCollister K, et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. HIV Clin Trials. 3.6 (2002):483-91.
  257. Ferencik, M., Ebringer, L. "Modulatory Effects of Selenium and Zinc in the Immune System."Folia Microbiol (Praha)48.3 (2003): 417-26.
  258. Rousseau, M. C., Molines, C., Moreau, J, et al. "Influence of Highly Active Antiretroviral Therapy on Micronutrient Profiles in HIV-Infected Patients." Ann Nutr Metab44.5-6 (2000): 212-216.
  259. Baum, M. K., Lai, S., Sales, S., Page, J. B., Campa, A. "Randomized, Controlled Clinical Trial of Zinc Supplementation to Prevent Immunological Failure Inhiv-Infected Adults." Clin Infect Dis 50.12 (2010): 1653-60. http://cid.oxfordjournals.org/content/50/12/1653.short
  260. Mehta, S., Fawzi, W. W. "Micronutrient Supplementation as Adjunct Treatment for HIV-Infected Patients." Clin Infect Dis 50.12 (2010): 1661-3.
  261. Zeng, L., Zhang, L. "Efficacy and Safety of Zinc Supplementation for Adults, Children and Pregnant Women with Hivinfection: Systematic Review." Trop Med Int Health (2011). doi: 10.1111/j.1365-3156.2011.02871.x. [Epub ahead of print] http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2011.02871.x/full
  262. Liao C et al. Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study. ChemMedChem. 2010 Jul 5;5(7):1053-66.
  263. Hooper, L. V., Gordon, J. I. "Commensal Host-Bacterial Relationships in the Gut." Science 292.5519 (2001): 1115-8.
  264. Ley, R. E., Turnbaugh, P. J., Klein, S., et al. "Microbial Ecology: Human Gut Microbes Associated with Obesity." Nature 444.7122 (2006): 1022-3.
  265. Mehandru, S., Tenner-Racz, K., Racz, P., et al. "The Gastrointestinal Tract Is Critical to the Pathogenesis of Acute HIV-1 Infection." J Allergy Clin Immunol 116.2 (2005): 419-22.
  266. Johnson, R. P. "How HIV Guts the Immune System." N Engl J Med 358.21 (2008): 2287-9.
  267. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1.1 (2008): 23-30.
  268. Furrie, E., Macfarlane, S., Kennedy, A., et al. " Synbiotic Therapy (Bifidobacterium Longum/Synergy 1) Initiates Resolution of Inflammation in Patients with Active Ulcerative Colitis: a Randomised Controlled Pilot Trial." Gut 54.2 (2005): 242-9.
  269. O'Mahony, L., McCarthy, J., Kelly, P., et al. "Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles." Gastroenterology 128.3 (2005): 541-51.
  270. Braat, H., van den Brande, J., van Tol, E., et al. "Lactobacillus Rhamnosus Induces Peripheral Hyporesponsiveness in Stimulated CD4+ T Cells via Modulation of Dendritic Cell Function." Am J Clin Nutr 80.6 (2004): 1618-25.
  271. Isolauri, E., Majamaa, H., Arvola, T., et al. "Lactobacillus Casei Strain GG Reverses Increased Intestinal Permeability Induced by Cow Milk in Suckling Rats." Gastroenterology 105.6 (1993): 1643-50.
  272. Madsen, K., Cornish, A., Soper, P., et al. "Probiotic Bacteria Enhance Murine and Human Intestinal Epithelial Barrier Function." Gastroenterology 121.3 (2001): 580-91.
  273. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2.12 (2007): e1308.
  274. Trois L, Cardoso EM, Miura E. "Use of Probiotics in HIV-Infected Children: a Randomized Double-Blind Controlled Study." J Trop Pediatr 54.1 (2008): 19-24.
  275. Anukam, K. C., Osazuwa, E. O., Osadolor, H. B., et al. " Yogurt Containing Probiotic Lactobacillus Rhamnosus GR-1 and L. Reuteri RC-14 Helps Resolve Moderate Diarrhea and Increases CD4 Count in HIV/AIDS Patients." J Clin Gastroenterol 42.3 (2008): 239-43.
  276. Irvine, S. L., Hummelen, R., Hekmat, S., et al. "Probiotic Yogurt Consumption Is Associated with an Increase of CD4 Count among People Living with HIV/AIDS." J Clin Gastroenterol 44.9 (2010): e201-5.
  277. Hummelen, R., Hemsworth, J., Changalucha, J., et al. "Effect of Micronutrient and Probiotic Fortified Yogurt on Immune-Function of Anti-Retroviral Therapy Naïve HIV Patients." Nutrients3 (2011): 897-909.